Biochemical Markers in the Early Diagnosis of Chronic Kidney Disease
Abstract
Chronic kidney disease (CKD) is defined as kidney damage or decreased kidney filtration rate for a period ≥3 months and affects no less than 12.2% of the adult population worldwide. With a progressive increase in its prevalence, it is estimated that CKD, due to urbanization, population aging, and other risk factors, will become one of the top 10 most significant global health problems worldwide. This will increase the financial burden on healthcare, ranging between $650 and $923 billion. Among the 10 leading causes of death worldwide, chronic kidney disease has caused an estimated 6.8 million deaths in 2013, resulting in a mortality rate of 15%. However, in the same period, a relative reduction of 2.9% was observed for these deaths, due to worldwide interventions, raising disease awareness and attention. CKD is a symptom of a myriad of complex afflictions and is not easily diagnosed or staged by a sole test. Moreover, although incidence is until the age of 60 either steady or declining, the global prevalence of CKD is greater in adults up to 74 years old. CKD risk factors encompass age, diabetes, cardiovascular disease, and hypertension. Since the younger population has been increasingly affected by, for example, diabetes mellitus or hypertension, greater concerns are raised in terms of life expectancy and healthcare financial burden. It is crucial, and of urgent need, to identify and diagnose patients with CKD at its early stages in order to manage both the disease and its comorbidities. To achieve this, apart from decreasing the expense to handle unexpected non-communicable diseases, it is also important to find new non-traditional biochemical markers. So far, besides the omnipresent Urea and Creatinine, biomarkers such as β2-microglobulin, Cystatin C, Neutrophil Gelatinase-Associated Lipocalin, and Kidney Injury Molecule-1 have been proposed. Nevertheless, it is necessary to unveil potential biomarkers that can be used in panel as an enhanced tool for the early diagnosis of chronic kidney disease.
References
I. Lousa, F. Reis, I. Beirão, R. Alves et al., "New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature," 2020. ncbi.nlm.nih.gov
M. Mizdrak, M. Kumrić, T. T. Kurir, and J. Božić, "Emerging biomarkers for early detection of chronic kidney disease," Journal of personalized, 2022. mdpi.com
… of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study," Journal of the …, 2021. nih.gov
H. Wu, D. Tang, M. Yun, H. Liu, S. Huang, and C. Yun, "Metabolic dysfunctions of intestinal fatty acids and tryptophan reveal immuno-inflammatory response activation in IgA nephropathy," Frontiers in …, 2022. frontiersin.org
Y. Yamaguchi, M. Zampino, R. Moaddel, T. K. Chen, "Plasma metabolites associated with chronic kidney disease and renal function in adults from the Baltimore Longitudinal Study of Aging," Metabolomics, 2021. nih.gov
Q. Li, Y. You, Y. Zeng, X. Wang, Z. Pan, and J. Pang, "Associations between plasma tryptophan and indole-3-propionic acid levels and mortality in patients with coronary artery disease," The American Journal of ..., 2022. sciencedirect.com
B. Yao, M. C. Giel, and Y. Hong, "Detection of kidney disease biomarkers based on fluorescence technology," Materials Chemistry Frontiers, 2021. latrobe.edu.au
K. Z. Liu, G. Tian, A. C. T. Ko, M. Geissler, and D. Brassard, "Detection of renal biomarkers in chronic kidney disease using microfluidics: Progress, challenges and opportunities," Biomedical, Springer, 2020. [HTML]
I. Lousa, F. Reis, I. Beirão, R. Alves, and L. Belo, "New potential biomarkers for chronic kidney disease management—A review of the literature," *International Journal of ...*, 2020. mdpi.com
N. C. Chesnaye, A. Ortiz, C. Zoccali, and V. S. Stel, "The impact of population ageing on the burden of chronic kidney disease," Nature Reviews, 2024. [HTML]
A. Forbes and H. Gallagher, "Chronic kidney disease in adults: assessment and management," Clinical Medicine, 2020. sciencedirect.com
I. Sandokji and J. H. Greenberg, "Plasma and urine biomarkers of CKD: a review of findings in the CKiD study," Seminars in nephrology, 2021. nih.gov
V. Radišić Biljak, L. Honović, J. Matica, B. Krešić et al., "The role of laboratory testing in detection and classification of chronic kidney disease: national recommendations," 2017. ncbi.nlm.nih.gov
D. Katagiri, F. Wang, J. C. Gore, R. C. Harris et al., "Clinical and experimental approaches for imaging of acute kidney injury," 2021. ncbi.nlm.nih.gov
J. H. Ix and M. G. Shlipak, "The promise of tubule biomarkers in kidney disease: a review," American Journal of Kidney Diseases, 2021. sciencedirect.com
S. Hussain, A. Habib, M. S. Hussain, and A. K. Najmi, "Potential biomarkers for early detection of diabetic kidney disease," Diabetes Research and …, 2020. [HTML]
T. Kongtasai, D. Paepe, E. Meyer, F. Mortier et al., "Renal biomarkers in cats: A review of the current status in chronic kidney disease," 2022. ncbi.nlm.nih.gov
S. Spencer, R. Desborough, and S. Bhandari, "Should Cystatin C eGFR Become Routine Clinical Practice?," 2023. ncbi.nlm.nih.gov
A. R. Bourgonje, A. E. Abdulle, M. F. Bourgonje, L. M. Kieneker et al., "Plasma Neutrophil Gelatinase-Associated Lipocalin Associates with New-Onset Chronic Kidney Disease in the General Population," 2023. ncbi.nlm.nih.gov
S. Roumeliotis, F. Mallamaci, and C. Zoccali, "Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update," Journal of Clinical Medicine, 2020. mdpi.com
O. Gungor, S. Ulu, N. B. Hasbal, and S. D. Anker, "Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?," Journal of Cachexia, vol. 2021, Wiley Online Library, 2021. wiley.com
